AKT control of PD-L1 traffic was similar in non-transformed and transformed cells and it was unaffected by whether the driver oncogene was mutant EGFR or KRAS, indicating this is a fundamental feature of PD-L1 biology and not specific to cancer cells or specific driver mutation. Here, KRAS is linked to cancer.